BEFIBRAT

This brand name is authorized in Germany

Active ingredients

The drug BEFIBRAT contains one active pharmaceutical ingredient (API):

1 Bezafibrate
UNII Y9449Q51XH - BEZAFIBRATE

Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL receptor-mediated lipoprotein catabolism.

Read about Bezafibrate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C10AB02 Bezafibrate C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates
Discover more medicines within C10AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: DE Bundesinstitut fĂźr Arzneimittel und Medizinprodukte Identifier(s): 06998086, 06998092, 07388792

Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈